Navigation Links
Biotest Pharmaceuticals Corporation Responds to Orphan Drug Act Announcement
Date:3/27/2008

BOCA RATON, Fla., March 27 /PRNewswire/ -- Biotest Pharmaceuticals Corporation, a leading developer of immunology biotherapeutic products, today responded to an announcement that a Hepatitis B Immune Globulin Intravenous (Human) product manufactured by another company has received Orphan Drug designation by the U.S. Food and Drug Administration (FDA) for the prevention of hepatitis B recurrence following orthotopic liver transplantation.

"The designation announced yesterday does not affect our ability to continue to provide Nabi-HB(R) to the marketplace. Nabi-HB has been the industry gold standard for the prevention of hepatitis B infection following accidental exposure to hepatitis B virus and many hospitals, physicians and patients have come to rely on Nabi-HB's long, safe and effective history since its approval in the late 1990s. We are committed to continuing to work with our partners and the medical and patient community to provide Nabi-HB to those who need it. Biotest Pharmaceuticals also is committed to continuing our research and development activities in the hepatitis liver transplant community," said Dr. Rainer Pabst, Chief Executive Officer of Biotest Pharmaceuticals.

Biotest Pharmaceuticals acquired Nabi-HB as part of the company's acquisition of Nabi Biopharmaceuticals' Biologics Strategic Business Unit in December 2007.

About Biotest Pharmaceuticals Corporation

Biotest Pharmaceuticals Corporation develops and manufactures pharmaceutical and biotherapeutic products with a specialization in immunology. Biotest Pharmaceuticals will offer the hyperimmunoglobulin Nabi- HB(R), a key product used in the prevention of hepatitis B. Biotest Pharmaceuticals also is currently working to develop additional products including a polyvalent immunoglobulin (IVIG, Phase III) and Civacir(R) (Phase IIb), for the prevention of hepatitis C in liver transplant patients. Biotest Pharmaceuticals was formed in 2007 as part of the Biotest AG a
'/>"/>

SOURCE Biotest Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Nabi Biopharmaceuticals Completes Sale of Nabi Biologics to Biotest AG
2. AUDIO from Medialink and Solvay Pharmaceuticals: Men with Type 2 Diabetes at Increased Risk for Low Testosterone Should Talk to Their Doctors
3. MAP Pharmaceuticals Appoints H. Ward Wolff to Board of Directors
4. Conatus Pharmaceuticals Appoints Anthony W. Fox, MD, Ph.D., as Chief Medical Officer
5. XTL Biopharmaceuticals Announces Financial Results for the Year Ended December 31, 2007
6. Dreier LLP Announces Class Action Lawsuit Against Vertex Pharmaceuticals Incorporated (VRTX)
7. Alseres Pharmaceuticals, Inc. Raises $5 Million
8. Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharmaceuticals
9. Transcept Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
10. Law Offices of Howard G. Smith Announces Class Action Lawsuit Against Vertex Pharmaceuticals Incorporated
11. Sagent Pharmaceuticals Launches Ciprofloxacin Injection, USP, 5% Dextrose Premix Bag
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... La Mirada, CA (PRWEB) , ... June 29, ... ... organizations, has announced that Dr. Gabriel Martin Del Campo is their newest FAA-certified ... Administration (FAA) physical examination is available for all fledging pilots seeking to obtain ...
(Date:6/29/2015)... ... June 29, 2015 , ... The Society for Immunotherapy ... (EMA) has granted accelerated approval of Bristol-Myers Squibb’s Opdivo® (nivolumab) for the treatment ... the approval of nivolumab for patients with metastatic melanoma in Europe represents a ...
(Date:6/29/2015)... ... ... Displays and Exhibits , a top online retailer of trade ... that include branding. Enter price code brand2015 for a ten percent discount on all ... promotional materials, all should integrate the company logo to communicate the brand. What is ...
(Date:6/29/2015)... ... 29, 2015 , ... Brittenford Systems, a provider of financial ... businesses across the United States, has announced that it has been named to ... year. , Based on company revenue and number of employees, Bob Scott’s Top ...
(Date:6/29/2015)... ... June 29, 2015 , ... Human Factors and Usability ... 16, 2015 — 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/humanfactors , ... engineering to the design of new products as well as to postmarket surveillance ...
Breaking Medicine News(10 mins):Health News:Healthpointe Now Offering FAA Physical Exams in San Bernardino County 2Health News:Society for Immunotherapy of Cancer Reacts to EMA Approval of Nivolumab for Treatment of Metastatic Melanoma 2Health News:Society for Immunotherapy of Cancer Reacts to EMA Approval of Nivolumab for Treatment of Metastatic Melanoma 3Health News:Stock Up on Logo Branding Tools Reduced this Month and Next Month from Displays and Exhibits 2Health News:Brittenford Systems Celebrates Fifth Consecutive Year on Bob Scott Insights Top 100 VARs 2Health News:Brittenford Systems Celebrates Fifth Consecutive Year on Bob Scott Insights Top 100 VARs 3Health News:FDAnews Announces Human Factors and Usability Studies: Understanding and Optimizing Interaction with Medical Devices Webinar, July 16, 2015 2Health News:FDAnews Announces Human Factors and Usability Studies: Understanding and Optimizing Interaction with Medical Devices Webinar, July 16, 2015 3
... focused new and improved interface. The most highlighting feature of this ... consumers to choose and buy their niche medicines any time. ... ... most reliable online pharmacy, launched a brand new customer focused, well ...
... for Two to International DestinationsSALT LAKE CITY, April 5 ... destination -- by winning it, with the launch of their ... Advanced." Schiff(R) will award seven grand prize winners a ... eight international destinations as well as 10,000 secondary prizes of ...
... 4 Inverness Medical Innovations, Inc. (NYSE: ... take charge of their health at home through the ... that it will attend the upcoming Goldman Sachs Leveraged ... 8, 2009 at the Goldman Sachs Conference Center located ...
... maker of lubricious HYDAK® hydrophilic coatings, and Agion Technologies, the ... co-marketing agreement to develop and promote a coatings product line ... ... Horsham, PA (PRWEB) April 4, 2009 -- ...
... Inc. (Nasdaq: BNVI ), a leader in the ... areas of women,s health and cancer, is scheduled to present ... City on April 9, 2009 at 3:45 p.m. MST.Mary Tagliaferri, ... The purpose of the presentation will be to update investors ...
... Departments Urge Public to Self-Report Suspected MeaslesHARRISBURG, Pa., April 3 ... Allegheny County Health Department and UPMC,s Children,s Hospital of Pittsburgh ... seen at Children,s Hospital. Exposures to measles may have occurred ... , ...
Cached Medicine News:Health News:Rxonlinetoday Launch Cyber Shop for FDA Approved Medicines 2Health News:Rxonlinetoday Launch Cyber Shop for FDA Approved Medicines 3Health News:Schiff Announces New 'Trip of a Lifetime' Sweepstakes 2Health News:Schiff Announces New 'Trip of a Lifetime' Sweepstakes 3Health News:Biocoat and Agion to Develop and Co-market Coatings for Medical Devices. 2Health News:Biocoat and Agion to Develop and Co-market Coatings for Medical Devices. 3Health News:Bionovo to Present at the Cambria Capital Investor Meeting 2Health News:Bionovo to Present at the Cambria Capital Investor Meeting 3Health News:Pennsylvania State Department of Health and Allegheny County Health Department Confirm Four Cases of Measles in Southwest Region 2Health News:Pennsylvania State Department of Health and Allegheny County Health Department Confirm Four Cases of Measles in Southwest Region 3
(Date:6/29/2015)... SAN FRANCISCO , June 29, ... company,s novel blood-draw technology has received CE Mark ... quality from the European Union. This regulatory milestone ... alternative to one of the most common procedures ... Velano Vascular,s proprietary device reduces the ...
(Date:6/29/2015)... , June 29, 2015 ... and predicted revenues ,Where is the market for dermatological ... market? Visiongain ,s new report shows you potential ... and prospects. Our 310 page report ... most lucrative areas in the industry and the future ...
(Date:6/29/2015)... Calif. , June 29, 2015  The ... innovative features to cars on the basis of ... The industry is now on the verge of ... cars. While automotive HWW non-critical features such as ... be present in 30 to 40 percent of ...
Breaking Medicine Technology:Velano Vascular Receives CE Mark For Novel Blood Draw Technology Designed to Reduce Needle Exposures for Hospitalized Patients and Healthcare Providers 2Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 2Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 3Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 4Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 5Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 6Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 7Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 8Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 2Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 3Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 4
... Expected in November 2008, BOTHELL, Wash., Oct. 9 ... the completion of patient enrollment and dosing,for the third ... and,efficacy of its formulation of 12-hour extended-release (ER) ibuprofen ... top-line,results from this pivotal trial in November 2008. Ibuprofen ...
... Will Reduce Animal Use in Cosmetics and Chemicals ... Corp. today announced,that results of a recently completed ... EpiDerm in vitro human skin tissue,equivalent. The test ... to be accepted as a validated alternative to ...
Cached Medicine Technology:SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 2SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 3MatTek's EpiDerm In Vitro Tissues Headed for Validation in Europe 2
... A concentrated enzymatic cleanser ... semi-automated hematology instruments. It ... all Abbott CELL-DYN® hematology ... instruments. The shelf life ...
Streck-CD3500 Hemoglobin/Lyse is a lytic reagent for the quantitative determination of hemoglobin on the Abbott CELL-DYN® 3500 and 3700. The shelf life is two years from the date of manufacture....
Streck-Diluent III Plus is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 3000, 3500 and 3700. The shelf...
Streck-Diluent IIIA is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 1700. The shelf life is one year f...
Medicine Products: